Revvity 84, -, 250µci (9.2

AFDX-384 is a drug targeting M₂ and M₄ muscarinic receptors, and is used for mapping receptor distribution in the brain. Muscarinic acetylcholine receptors (mAChRs) are GPCRs that play a role in the parasympathetic nervous system. Muscarinic acetylcholine receptors are potential targets for dementia and schizophrenia.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET1041:

A.V. Terry, D.A. Gearhart, S.P. Mahadik, S. Warsi, J.L. Waller, Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain, In Neuroscience, Volume 140, Issue 4, 2006, Pages 1277-1287.